UROVYSION BLADDER CANCER RECURRENCE KIT

K013785 · Vysis · MMW · Feb 8, 2002 · Immunology

Device Facts

• Record ID: K013785
• Device Name: UROVYSION BLADDER CANCER RECURRENCE KIT
• Applicant: Vysis
• Product Code: MMW · Immunology
• Decision Date: Feb 8, 2002
• Decision: SESE
• Submission Type: Abbreviated
• Regulation: 21 CFR 866.6010
• Device Class: Class 2

Intended Use

The UroVysion Bladder Cancer Recurrence Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder. Results from the UroVysion Kit are intended for use as a noninvasive method for monitoring for turnor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

Device Story

UroVysion Kit uses fluorescence in situ hybridization (FISH) to detect chromosomal abnormalities in voided urine specimens. Input: urine samples fixed on slides. Process: 4-color, 4-probe DNA mixture (CEP 3 SpectrumRed, CEP 7 SpectrumGreen, CEP 17 SpectrumAqua, LSI 9p21 SpectrumGold) hybridizes to target chromosomes; analyst visually identifies fluorescent signals via microscopy. Output: qualitative assessment of aneuploidy (chromosomes 3, 7, 17) or 9p21 locus loss. Used in clinical laboratories by trained analysts. Results assist physicians in monitoring for bladder cancer recurrence alongside cystoscopy. Benefits include noninvasive detection of recurrence, potentially reducing reliance on invasive procedures.

Clinical Evidence

Multi-center, prospective, longitudinal study (n=176 unique patients). Primary endpoint: agreement with cystoscopy/histology standard of care. UroVysion showed 71.0% positive agreement and 65.8% negative agreement. Specificity study (n=357) showed 93.0% overall specificity. Longitudinal follow-up (n=104) showed statistically significant difference in recurrence rates between FISH-positive/cystoscopy-negative and FISH-negative/cystoscopy-negative groups (p=0.014). Bench testing confirmed hybridization efficiency (≥87%) and analytical specificity.

Technological Characteristics

Fluorescence in situ hybridization (FISH) assay using DNA probes for chromosomes 3, 7, 17 and 9p21 locus. Manual or semi-automated processing (VP2000 Sample Processor and HYBrite instruments). Visual microscopic analysis. No software-based automated image analysis described.

Indications for Use

Indicated for monitoring bladder cancer recurrence in patients previously diagnosed with transitional cell carcinoma of the bladder. Uses voided urine specimens.

Regulatory Classification

Identification

A tumor-associated antigen immunological test system is a device that consists of reagents used to qualitatively or quantitatively measure, by immunochemical techniques, tumor-associated antigens in serum, plasma, urine, or other body fluids. This device is intended as an aid in monitoring patients for disease progress or response to therapy or for the detection of recurrent or residual disease.

Special Controls

*Classification.* Class II (special controls). Tumor markers must comply with the following special controls: (1) A guidance document entitled “Guidance Document for the Submission of Tumor Associated Antigen Premarket Notifications (510(k)s) to FDA,” and (2) voluntary assay performance standards issued by the National Committee on Clinical Laboratory Standards.

Predicate Devices

• Bard (Bion) BTAstat Test

Submission Summary (Full Text)

{0}------------------------------------------------

K013785

Image /page/0/Picture/1 description: The image shows a date, "FEB 0 8 2002". The month is February, the day is the 8th, and the year is 2002. The text is in a bold, sans-serif font. The background is white.

Vysis, Inc. 3100 Woodcreek Dr. Downers Grove, IL 60515 Tel: [phone] Fax: [phone] Contact: Russel K. Enns, Ph.D.

# 510(k) Summary: Safety and Effectiveness Information for the UroVvsion™ Bladder Cancer Recurrence Kit

January 28, 2002

Trade Name Vysis™ UroVysion™ Bladder Cancer Recurrence Kit

Common or Usual Name Fluorescence in situ hybridization (FISH) reagents

Classification Name Class II IVD Device

Predicate Legally Marketed Device Bard® (Bion) BTAstat™ Test

#### Description of the Device

The UroVysion Kit is based upon fluorescence in situ hybridization (FISH) DNA probe technology. The UroVysion probes are fluorescently labeled nucleic acid probes for use in in situ hybridization assays on urine specimens fixed on slides. . The UroVysion Kit consists of a 4-color, four-probe mixture of DNA probe sequences homologous to specific regions on chromosomes 3, 7, 9, and 17. The UroVysion probe mixture consists of Chromosome Enumeration Probe (CEP®) 3 SpectrumRed™, CEP 7 SpectrumGreen™, CEP 17 SpectrumAqua™, and Locus Specific Identifier (LSI®) 9p21 SpectrumGold TM .

#### Intended Use

The UroVysion Bladder Cancer Recurrence Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder. Results from the UroVysion Kit are intended for use as a noninvasive method for monitoring for turnor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

{1}------------------------------------------------

#### Different Technological Characteristics

Both the UroVysion Kit and the BTAstat test use the same specimen collection and preparation techniques in clinical practice. Thus, no new issues of safety with respect to patient care are introduced by the FISH technique; both the UroVysion Kit and the BTAstat test start with the same patient specimen (i.e., voided urine).

The major differences between the two tests are that they detect different substances and use different detection methods. Briefly, the UroVysion Kit uses DNA probes for specific regions on chromosomes 3, 7, 9 and 17 that bind to the target chromosomes by the DNA hybridization reaction. The actual binding mechanism of the UroVysion Kit is via specific complementary base pairing. In contrast, the BTAstat test is a lateral flow assay that detects the presence of bladder tumor associated antigen through antigen-specific antibodies. Also, the necessary visual interpretation of the results of the UroVysion Kit and of the BTAstat test is different. For the BTAstat test, urine is allowed to react with a colloidal gold-conjugated antibody and the results are determined qualitatively by the presence or absence of a line on the test stick. For the UroVysion Kit, the analyst visually recognizes chromosomes 3, 7 and 17, and the 9p21 locus by the fluorescent signal carried by the DNA probe mixture.

Even though the technological characteristics are different between the BTAstat test (antigen test) and the UroVysion test (DNA probe test), both test are intended for use to monitor for the recurrence of bladder cancer from voided urine specimens. The overall performance of the UroVysion test was demonstrated to be substantially equivalent.

Safety and effectiveness issues evaluated for the UroVysion Kit included the following: prospective, comparative methods evaluation for monitoring bladder cancer recurrence; specificity evaluation in healthy and unhealthy patients (without previous diagnosis of bladder cancer); interference assessment; and reproducibility studies.

{2}------------------------------------------------

#### Non-Clinical Parameters

#### Hybridization Efficiency

On the ProbeChek™ quality control slides run in conjunction with the clinical trials, 1.5% (4/261) of the targets failed due to lack of hybridization. These slides are prepared from cultured human bladder carcinoma (positive target) and normal lymphoblast (neqative target) cell lines, and represent the best-case scenario for hybridization efficiency. Thus, under these conditions, the hybridization efficiency was found to be 98.5%, with <2% cells having no signal for any of the probes.

In a reproducibility study conducted on specimens prepared from human urine cell lines. 76 of 80 specimens vielded informative results on the first attempt. Of the 4 uninformative specimens, 3 were due to lack of hybridization. Therefore the hybridization efficiency was found to be 96.2%, based on the following definition:

% Hybridization Efficiency = 100-[hybridization failures/(informative results + hybridization failures)]*100

In a specificity study conducted on urine specimens from patients with no history. of bladder cancer, 230 of 309 specimens vielded informative results on the first . attempt and 18 of the uninformative results were due to lack of hybridization: resulting in a hybridization efficiency of 92.7% (see "Specificity: Technical . Performance: Informative vs. Non-Informative Results" for more details). Similarly, in a clinical study conducted on urine specimens from patients with a history of bladder cancer. 175 of 251 specimens vielded informative results on the first attempt and 26 of the 76 uninformative results were due to lack of hybridization. The hybridization efficiency among these specimens was found to be 87%. Thus, under these conditions, which simulate the normal clinical practice, the hybridization efficiency was found to be ≥87% (see "Performance vs. Standard of Care: Technical Performance: Informative vs. Non-Informative Results" for more details).

#### Analytical Specificity

Locus specificity studies were performed with metaphase spreads according to standard Vysis QC protocols. A total of 42 metaphase spreads were examined sequentially by reverse DAPI banding to identify chromosomes 3, 7 and 17, and the 9p21 locus, followed by FISH. No cross-hybridization to other chromosome loci was observed in any of the 42 cells examined; hybridization was limited to the intended target regions of the four probes.

{3}------------------------------------------------

#### Interference

Three voided urine pools (one male, one female, one male/female mix) from normal healthy volunteers were spiked with the substances listed in Table 1 and assayed with the UroVysion Kit to test for possible assay interference. Replicate samples for each urine pool were evaluated for each substance (i.e., 6 samples per substance tested); 25 consecutive cells were enumerated for each specimen. No interference was detected from any of the substances tested; results from all samples were negative (i.e., <4 abnormal cells as defined in this package insert). The highest concentrations tested for each substance are shown in Table 1.

| Substances Tested for Assay Interference | |
|------------------------------------------|---------------------------------------------------------------------------|
| Substance | Highest Concentration Tested |
| Possible Urine Constituents | |
| Albumin | 1.0 g/dL |
| Ascorbic Acid | 5 g/dL |
| Bilirubin (unconjugated) | 2 mg/mL |
| Hemoglobin | 100 mg/mL |
| IgG | 10 mg/dL |
| Red Blood Cells (human) | 1 x 106 cells/mL |
| White Blood Cells (human) | 1 x 106 cells/mL |
| Sodium Chloride | 730 mg/dL |
| Uric Acid | 250 mg/dL |
| Caffeine | 117 mg/dL |
| Ethanol | 1% (v/v) |
| Nicotine | 28 mg/dL |
| Possible Microbial Contaminants | |
| Candida albicans | 2.5 x 1010 CFU/mL |
| Escherichia coli | 2.5 x 1010 CFU/mL |
| Pseudomonas aerugenosa | 2.5 x 1012 CFU/mL |
| Therapeutic Agents | |
| Acetaminophen | 5.2 g/dL |
| Acetylsalicylic Acid | 5.2 g/dL |
| Ampicillin | 600 mg/dL |
| BCG | 20 mg/dL |
| Doxorubicin-HCl | 10 mg/dL |
| Mitomycin C | 10 mg/dL |
| Nitrofurantoin | 50 mg/dL |
| Phenazopyridine-HCl | 200 mg/dL |
| Thiotepa | 10 mg/dL |
| Trimethoprin | 50 mg/dL |
| Preservatives | |
| Vysis, Inc. standard: 2% Carbowax | 2% Carbowax/50% ethanol solution<br>(33 ml urine with 17 mL preservative) |
| UroCor, Inc. fixative | 50/50 with urine |
| CytoRichRed (Autocyte) | 50/50 with urine |
| Saccamono's solution | 50/50 with urine |
| PreservCyt solution (Cytyc) | 50/50 with urine |
| 100% Ethanol | 50/50 with urine |

| Table 1 | |
|------------------------------------------|------------------------------|
| Substances Tested for Assay Interference | |
| Substance | Highest Concentration Tested |

{4}------------------------------------------------

#### Reproducibility

#### Reproducibility of Patient Samples

Conducting reproducibility studies on real patient urine specimens was not feasible, since one patient cell pellet does not yield enough cells to reasonably split the specimen between observers. Hence the reproducibility of results on the number of morphologically abnormal cells was not assessed.

#### Reproducibility of Bladder Carcinoma Cell Culture Specimens

To assess the reproducibility of the UroVysion assay, analyses of the signal distributions for CEP 3, CEP 7, CEP 17 and LSI 9p21 were assessed for inter-site (4) reproducibility on slides prepared from 4 different bladder carcinoma cell lines. Four specimens prepared from human bladder carcinoma cell lines with normal (one specimen) and abnormal (3 specimens) signal distribution were evaluated for CEP 3, CEP 7, CEP 17 and LSI 9p21 according to the instructions for analysis of quality control slides in this package insert (see "Interpretation of Results: Analysis of Quality Control Slides"). Each site assayed four replications of the same specimen on each of four assay days (a different specimen each day), using a single probe lot for all specimens. On each assay day, an additional "wild card" specimen was added to eliminate bias and was not included in the data analysis. Each specimen was evaluated by one observer at each site. Informative results were obtained in 95.0% (76/80) of the specimens on the first attempt. Hybridization of all replacement slides was successful.

The mean, standard deviation, and percent CV of the average number of signals . for the four probes is shown in Table 2. As shown in this table, the mean number of signals for each probe varies within a narrow range. The absence of LSI 9p21 signals in specimen 2 causes a large %CV for this probe, but this specimen is still easily classified as having a loss of the 9p21 locus; in 95% of the observations on this specimen (19/20) the average number of LSI 9p21 signals was <0.2.

There were no false negative results in this study of human bladder carcinoma cell lines; all (48/48) evaluations of specimens 2, 3 and 4 (16 each) would have been classified as positive by the definition of ≥4 cells with gains of multiple chromosomes (3 or more signals for two or more of CEP 3, CEP 7 or CEP 17), or ≥12 cells with homozygous loss of 9p21 (0 LSI 9p21 signals). Of the 16 evaluations of the normal specimen, one would have been classified as positive using the above definition; this case showed 6 cells with gains of multiple chromosomes.

{5}------------------------------------------------

| | Table 2<br>Between-Site Reproducibility | | | | |
|----------|-----------------------------------------|-----------|-----------|-----------|-----------|
| Specimen | Statistics | CEP 3 | CEP 7 | CEP 17 | LSI 9p21 |
| 1 | Mean | 2.21 | 2.12 | 2.14 | 2.19 |
| | S.D. | 0.15 | 0.12 | 0.12 | 0.21 |
| | C.V. (%) | 6.79% | 5.52% | 5.66% | 9.66% |
| | Range | 2.08-2.68 | 1.92-2.40 | 1.96-2.52 | 2.00-2.92 |
| | n | 16 | 16 | 16 | 16 |
| 2 | Mean | 3.95 | 4.31 | 3.42 | 0.03 |
| | S.D. | 0.10 | 0.25 | 0.16 | 0.07 |
| | C.V. (%) | 2.49% | 5.76 | 4.76% | 220.44% |
| | Range | 3.84-4.16 | 3.76-4.84 | 3.16-3.72 | 0.00-0.24 |
| | n | 16 | 16 | 16 | 16 |
| 3 | Mean | 4.28 | 3.55 | 3.42 | 3.86 |
| | S.D. | 0.32 | 0.34 | 0.25 | 0.47 |
| | C.V. (%) | 7.58% | 9.47% | 7.21% | 12.14% |
| | Range | 3.88-5.04 | 3.12-4.24 | 3.04-3.96 | 3.16-4.72 |
| | n | 16 | 16 | 16 | 16 |
| 4 | Mean | 3.18 | 3.88 | 3.84 | 3.85 |
| | S.D. | 0.15 | 0.10 | 0.10 | 0.15 |
| | C.V. (%) | 4.63% | 2.45% | 2.70% | 3.90% |
| | Range | 2.96-3.52 | 3.64-4.04 | 3.64-4.12 | 3.56-4.24 |
| | n | 16 | 16 | 16 | 16 |

் பட்டியல் விளைவிடம் இருக்கும் பெற்ற விடுத்துகள் வரையும் இருக்கும் விளைவிட்டுள்ள விளைவி
க்கலைக்கு கிராமம் குறிக்கும் இருக்கும் பொருள்கள் விளைவியல் விளைவிட்டுள்ள விளைவியாக வி

Company Confidential, Vysis, Inc. 1

::

:

and the country

{6}------------------------------------------------

#### Specificity

#### Study Summary

Study Gammary
A multi-center, prospective study was conducted to establish the specificity of the I I mail. on test in urine from healthy volunteers and urology patients without prior history or clinical evidence of bladder cancer.

# Technical Performance: Informative vs. Non-Informative Results

A total of 315 patient visits were conducted in conjunction with this trial, resulting in 309 usable office visits. The 6 unusable visits included one that failed to meet the study eligibility criteria, 4 with insufficient urine volume, and in 1 cases urine was not sent to the testing laboratory. FISH assay and analysis on the 309 usable office visits resulted in informative results in 230 specimens on the first attempt. Of the 79 specimens that failed to yield informative results on the first attempt, only 18 were due to hybridization failures. The hybridization efficiency for the first assay attempt was 93%. The remaining non-informative assays were the result of poor specimen quality (e.g., insufficient number of cells) or technical error (e.g., oil under coverslip). Repeat assays were conducted on 67 specimens; 12 of these 79 specimens had insufficient volume remaining to repeat the assay. Of the 67 repeat assays, 45 yielded informative results, leaving 34 specimens classified as "non-informative" (including 12 cases with insufficient volume for repeat assay). In summary, 89% of the cases yielded an informative result on the first or second attempt. Since several patients thealth informative food into multiple categories, the 275 patient specimens yielding informative results represented 357 data points. The patient population is summarized by category in Table 3.

| Patient Population | |
|-------------------------------|---------------|
| Condition | # of Patients |
| Healthy Donors | 59 |
| Non-Smokers | 50 |
| Smokers | 9 |
| Non-GU Benign Diseases | 48 |
| Non-GU Cancer | 3 |
| GU Diseases | 184 |
| BPH | 58 |
| Microhematuria | 15 |
| Interstitial Cystitis | 11 |
| Inflammation/Infection: Other | 17 |
| STD | 2 |
| Other | 81 |
| GU Cancer (non-bladder) | 61 |
| Prostate | 58 |
| Renal | 3 |
| GU Trauma | 2 |
| Total: | 357 |

| Table 3 | |
|--------------------|-----|
| Patient Population | |
| | # o |

Company Confidential. Vysis, Inc.

{7}------------------------------------------------

#### Specificity

The overall specificity of the UroVysion test in this patient population was 93.0% (332/357). The overall specificity was calculated based on all patients and all conditions; patients with medical conditions falling in multiple categories and/or multiple conditions within the same category were counted for each individual condition. A summary of the overall specificity and the specificity by category is shown in Table 4. To eliminate the potential bias of including multiple data points for any particular patient, the specificity was also calculated on "unique cases", where each patient was counted only once, regardless of the number of medical conditions present. The specificity among the unique cases was 94.5% (260/275, Table 4).

| Summary: UroVysion Kit Specificity | |
|------------------------------------|-----------------|
| Overall Specificity | 93.0% (332/357) |
| Unique Patients | 94.5% (260/275) |
| Healthy vs. Non-Healthy | |
| Healthy | 100% (59/59) |
| Non-Healthy | 93.1% (201/216) |
| Smokers vs. Non-Smokers1 | |
| Smokers | 95.2% (40/42) |
| Non-Smokers | 94.7% (234/247) |
| Individual Categories2 | |
| Healthy Donors | 100% (59/59) |
| Healthy non-smokers | 100% (50/50) |
| Healthy smokers | 100% (9/9) |
| Non-GU Benign Diseases | 91.7% (44/48) |
| Non-GU Cancer3 | 66.7% (2/3) |
| GU Diseases | 91.9% (169/184) |
| BPH | 91.4% (53/58) |
| Microhematuria | 86.7% (13/15) |
| Interstitial Cystitis | 90.7% (10/11) |
| Inflammation/Infection: Other | 100% (17/17) |
| STD | 100% (2/2) |
| Other | 91.4% (74/81) |
| GU Cancer (non-bladder) | 91.8% (56/61) |
| Prostate | 91.4% (53/58) |
| Renal | 100% (3/3) |
| GU Trauma | 100% (2/2) |

| Table 4 | | | | | |
|------------------------------------|--|--|--|--|---------------|
| Summary: UroVysion Kit Specificity | | | | | |
| Specificity | | | | | 93.0% (33/35) |

Smoking status unknown in 1 patient.

2 Some non-healthy patients had health conditions falling into multiple disease categories, resulting in totals >275 for individual disease categories. 3Non-GU cancers included breast (1), colon (1), and leukemia (1)

Based on the patient population in this study, the UroVysion test demonstrated an overall specificity of 93.0% (332/357), with a 100% specificity (59/59) among healthy patients. The specificity among unique cases was 94.5% (260/275). The false positive results found in 15 patients represented the following categories (note that some patients had health conditions falling into multiple disease categories); non

{8}------------------------------------------------

genitourinary (GU) benign diseases (3), non-GU cancer (2), GU diseases (15), and GU cancer (5). These results indicate that the test is highly specific in this patient group, which reinforces the fact that FISH does not generate artificial aneuploidy determinations; the FISH probes react only with the intended chromosomes.

#### Performance vs. Standard of Care

#### Study Summary

A multi-center, prospective, longitudinal study was conducted to further define the performance characteristics of the UroVysion Kit relative to cystoscopy followed by histology, the standard of care for monitoring for disease recurrence in patients previously diagnosed with bladder cancer. The comparative reference used for all percent agreement calculations was cystoscopy with histology confirmation for positive or suspicious cystoscopies. If a patient had a positive cystoscopy but histology was absent (e.g., the lesion was fulgurated), then the specimen was considered positive for bladder cancer. If a test had a suspicious cystoscopy but histology was absent, then the case was omitted from analysis. A total of 309 patient visits were conducted at 21 investigation sites, resulting in 251 usable office visits. The 58 unusable visits included 17 that did not meet the eligibility criteria, 16 with insufficient urine volume, 10 with suspicious cvstoscopies but no histology, and in 15 cases urine was not sent to the testing. laboratories. Urine processing and analysis were conducted at one centralized testing laboratory. FISH assay and analysis on the 251 usable office visits in the resulted in 234 informative results, representing 176 unique patients. For patients who experienced a recurrence during the trial (as determined by is a cystoscopy and/or histology), the first positive visit was used (i.e., the visit at which the diagnosis of recurrence was established). For the non-recurring patients, the last negative visit was used for those patients with more than one visit. The demographics for the 176 unique patients are summarized in Table 5.

| Table 5 | |
|----------------------|---------------|
| Patient Demographics | |
| Sex | |
| Male | 132 |
| Female | 44 |
| Race | |
| Caucasian | 153 |
| African American | 3 |
| Hispanic | 3 |
| Other | 13 |
| Unknown | 4 |
| Age | |
| Range | 36 - 98 years |
| Average | 71 years |

{9}------------------------------------------------

Technical Performance: Informative vs. Non-Informative Results FISH assays on 70% (175/251) of the eligible study specimens were informative on the first attempt. Of the 76 specimens that failed to yield informative results on the first attempt, only 26 were due to hybridization failures. The hybridization efficiency for the first assay attempt was 87%. The remaining non-informative assays were the result of poor specimen quality (e.g., insufficient number of cells) or technical error (e.q., broken slide).

Repeat assays were conducted on 70 specimens; six of the 76 specimens had insufficient volume remaining to repeat the assay. Of the 70 repeat assays, 59 yielded informative results, leaving 17 specimens classified as "non-informative" (including the 6 cases with insufficient volume for repeat assay). In summary, over 93% of the cases vielded an informative result on the first or second attempt.

#### Performance vs. Standard of Care

Of the eligible patients with informative FISH results, 62 were positive by cystoscopy/histology. A breakdown of the number of tumors by stage and grade is shown in Table 6.

| Number of Tumors, by Stage and Grade | | | | | | | |
|--------------------------------------|----|-----------|----|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--|
| Tumor | | | | Tumor Grade | | | |
| Stage : | | ND - 1 - | | : 2 . : 3 . 3 | Unknown | Total | |
| ND | | 11 : 0 :: | | 1: 00 : 0 : 000 | 0 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | 11 . | |
| Ta | 0 | 20 | 6 | റ | 0 | 32 | |
| 11 | 0 | O | 2 | 3 | | ರ | |
| T2 | 0 | 0 | 0 | 1 | | | |
| Tis | 0 | O | () | | 0 | | |
| Unknown | O | 2 | | . O | 0 | | |
| Total | 11 | 22 | g | 18 | 2 | 62 | |

# Table 6

ND = not assigned or no biopsy

Table 7 shows the performance of the UroVysion Kit, relative to cystoscopy / histology, by tumor stage and grade for all cases with biopsy information available. The UroVysion Kit showed greatest agreement of positive results (100%) among the most severe tumors (T2 and Tis), when compared to cystoscopy/histology.

{10}------------------------------------------------

| Table 7 |
|--------------------------------------------------------------------------------------------------------------------------|
| Comparison of UroVysion vs. Cystoscopy/Histology for Detection<br>of Bladder Cancer Recurrence by Tumor Stage and Grade* |
| Agreement of (+) Results (%) |

| Stage: | | |
|---------------|---------------|--|
| All | 36/48 (75.0%) | |
| Ta, Grade 1 | 11/20 (55.0%) | |
| Ta, Grade 2,3 | 10/12 (83.3%) | |
| T1 | 5/6 (83.3%) | |
| T2 | 3/3 (100%) | |
| Tis | 7/7 (100%) | |
| Grade: | | |
| All | 36/49 (73.5%) | |
| 1 | 12/22 (54.5%) | |
| 2 | 7/9 (77.8%) | |
| 3 | 17/18 (94.4%) | |

*Biopsy was not performed in 11 cases. In addition, no stage was assigned in 3 cases and no grade in 2.

Table 8 shows a comparison of the performance of the UroVysion Kit relative to cystoscopy followed by histology. Overall, FISH analysis with the ========================================================================================================= UroVysion Kit demonstrated a percent agreement of positive results of 71.0% and a percent agreement of negative results of 65.8% when compared to the results of cystoscopy, followed by histology in the case of positive or suspicious cystoscopy (Note: A positive cystoscopy without a biopsy was considered positive in this analysis).

# Table 8 Comparison of UroVysion vs. Cystoscopy/Histology for Detection of Bladder Cancer Recurrence

| | Cysto/Histo | | |
|-----------------------------------------------------------|-------------|-----|-------|
| FISH | + | - | Total |
| + | 44 | 39 | 83 |
| - | 18 | 75 | 93 |
| Total | 62 | 114 | 176 |
| Agreement of (+) results = 71.0% (95% CI = 58.1% - 81.8%) | | | |

Agreement of (-) results = 65.8% (95% CI = 56.3% - 74.4%) Overall Agreement = 67.6% (95% Cl = 60.2% - 74.5%) (+) Predictive Value = 53.0% (95% Cl = 41.7%-64.1%) (-) Predictive Value = 80.6% (95% CI = 71.1% - 88.1%) Prevalence = 35.2% (95% Cl = 28.2% - 42.8%) p = < 0.0001 (Fisher's Exact Test)

{11}------------------------------------------------

The positive and negative predictive values of the UroVysion Test could be determined for prevalence rates of 10%, 20% and 30%; these are presented in Table 9. This extrapolation assumed a percent agreement of positive results of 71.0% and a percent agreement of negative results of 65.8% (Table 8).

| Table 9 |
|------------------------------------------------------------------------------------------|
| Hypothetical Positive Predictive and Negative Predictive Values of the<br>UroVysion Test |

| Bladder Cancer<br>Recurrence Prevalence | PPV | NPV |
|-----------------------------------------|-------|-------|
| 10% | 18.7% | 95.3% |
| 20% | 34.2% | 90.1% |
| 30% | 47.1% | 84.1% |

Table 10 shows a comparison of the performance of the UroVysion Kit relative to cystoscopy/ histology in patients who had received their last treatment with intravesical BCG within 3 months of FISH testing. The mean time duration of BCG treatment was 1.3 months (range 0.4-3.4 months). The mean time between the last BCG treatment and FISH testing among these patients was 1.3 months; the range was 0 (treatment ongoing at the time of FISH testing) to 3 months. Three of the 12 true positive cases were Tiss three were stage Ta grade 1, three were stage Ta grade 3, two were stage TA s grade 3, and one was stage T2 grade 3 (muscle invasive); the one false: negative case was stage Ta grade 1.

#### Table 10 Comparison of FISH vs. Cystoscopy/Histology for Detection of Bladder Cancer Recurrence in Patients on BCG Therapy within 3 Months Cysto/Histo

| | Cysto/histo | | |
|-----------------------------------------------------------|-------------|----|-------|
| FISH | + | - | Total |
| + | 12 | 10 | 22 |
| - | 1 | 16 | 17 |
| Total | 13 | 26 | 39 |
| Agreement of (+) results = 92.3% (95% CI = 64.0% - 99.8%) | | | |

Agreement of (-) results = 61.5 % (95% Cl = 40.6% - 79.8%) Overall Agreement = 71.8% (95% Cl = 55.1% - 85.0%) (+) Predictive Value = 54.5% (95% CI = 32.2% - 75.6%) (-) Predictive Value = 94.1% (95% CI = 71.3% - 99.9%) Prevalence = 33.3% (95% Cl = 19.1% - 50.2%) p = 0.0014 (Fisher's Exact Test)

{12}------------------------------------------------

#### Substantial Equivalence vs. BTAstat Test

In the clinical study described above, the performance of the UroVysion test was also compared to that of the BTAstat test to establish substantial equivalence of the two tests. Urine specimens from each of the 176 unique patients (first positive, last negative office visit) were also analyzed by the BTAstat test. Cytology was also performed on the study specimens and results are included for information purposes.

Tables 11 and 12 show the percent agreement of results of the UroVysion test, the BTAstat test and cytology by tumor stage and tumor grade. The UroVysion test showed greater percent agreement of positive results for all tumor stages, including 100% agreement for T2 and Tis tumors.

| Table 11 | | | |
|----------------------------------------------------------|----------|-------------|----------------|
| Percent Agreement of (+) Results Analysis by Tumor Stage | | | |
| Ta, 1 – Total: 20 Cases | | | |
| 55.0% | FISH | 11 Positive | 9 Negative |
| 20.0% | Cytology | 4 Positive | 16 Negative |
| 30.0% | BTAstat | 6 Positive | 14 Negative |
| Ta 2,3 – Total: 12 Cases | | | |
| 83.3% | FISH | 10 Positive | 2 Negative |
| 33.3% | Cytology | 4 Positive | 8 Negative |
| 83.3% | BTAstat | 10 Positive | 2 Negative |
| T1 – Total: 6 Cases | | | |
| 83.3% | FISH | 5 Positive | 1 Negative |
| 66.7% | Cytology | 4 Positive | 2 Negative |
| 83.3% | BTAstat | 5 Positive | 1 Negative |
| T2 – Total: 3 Cases | | | |
| 100% | FISH | 3 Positive | 0 Negative |
| 33.3% | Cytology | 1 Positive | 2 Negative |
| 66.7% | BTAstat | 2 Positive | 1 Negative |
| Tis – Total: 7 Cases | | | |
| 100% | FISH | 7 Positive | 0 Negative |
| 33.3% | Cytology | 2 Positive | 4 Negative |
| 42.9% | BTAstat | 3 Positive | 4 Negative |
| | | | 1 inconclusive |

hree (3) cases were considered Unknown by Central Pathology for Tumor

{13}------------------------------------------------

| Table 12 | | | | |
|----------------------------------------------------------|----------|-------------|-------------|----------------|
| Percent Agreement of (+) Results Analysis by Tumor Grade | | | | |
| Grade 1 - Total: 22 Cases | | | | |
| 54.5% | FISH | 12 Positive | 10 Negative | |
| 18.2% | Cytology | 4 Positive | 18 Negative | |
| 27.3% | BTAstat | 6 Positive | 16 Negative | |
| Grade 2 - Total: 9 Cases | | | | |
| 77.8% | FISH | 7 Positive | 2 Negative | |
| 44.4% | Cytology | 4 Positive | 5 Negative | |
| 77.8% | BTAstat | 7 Positive | 2 Negative | |
| Grade 3 - Total: 18 Cases | | | | |
| 94.4% | FISH | 17 Positive | 1 Negative | |
| 41.2% | Cytology | 7 Positive | 10 Negative | 1 inconclusive |
| 72.2% | BTAstat | 13 Positive | 5 Negative | |

NOTE: Two (2) cases were considered Unknown by Central Pathology for Tumor Grade.

Table 13 shows a comparison of the performance of the BTAstat test relative to cystoscopy/histology among the unique patients (first positive, last negative office visit). Overall, analysis with the BTAstat test demonstrated a percent agreement of positive results of 50.0% and a percent agreement of negative results of 69.3% when compared to the results of cystoscopy followed by histology in the case of positive or suspicious cystoscopy. (Note: A positive cystoscopy without a biopsy was considered positive in this analysis). In a comparison of the UroVysion Kit with cystoscopy/ histology on the same dataset (Table 8), the UroVysion Kit showed a percent agreement of positive results of 71.0% and a percent agreement of negative results of 65.8% (Table 8).

#### Table 13 Comparison of BTAstat vs. Cystoscopy/Histology for Detection of Bladder Cancer Recurrence Cysto/Histo

| | | Cysto/histo | | |
|---------|-------|-------------|-----|-------|
| | | + | - | Total |
| BTAstat | + | 31 | 35 | 66 |
| | - | 31 | 79 | 110 |
| | Total | 62 | 114 | 176 |

Agreement of (+) results = 50.0% (95% Cl = 37.0% - 63.0%) Agreement of (-) results = 69.3% (95% C1 = 60.0% - 77.6%) Overall Agreement = 62.5% (95% Cl = 54.9% - 69.7%) (+) Predictive Value = 47.0% (95% CI = 34.6% - 59.7%) (-) Predictive Value = 71.8% (95% CI = 62.4% - 80.0%) Prevalence = 35.2% (95% CI = 28.2% - 42.8%)

Company Confidential, Vysis, Inc.

{14}------------------------------------------------

Figure 1 compares the percent agreement of results for FISH, BTAstat and cytology (unique patient visits), relative to cystoscopy/histology. The UroVysion test's two tail lower 95% CI for percent agreement of positive, negative and overall results was 58.1%. 56.3% and 60.2%, respectively. On the corresponding dataset assayed with the BTAstat test, the scores minus 15% were 35.0%, 54.3% and 47.5%, respectively. Thus, the criteria for substantial equivalence of the UroVysion assay to the BTAstat test were met; the 95% Cls for UroVysion are greater than the BTAstat scores minus 15%. This is represented graphically in Fiqure 1; the error bars represent the upper and lower 95% CIs for the UroVysion test results and the test score minus 15% for the BTAstat test results. Again, as shown in the figure, in each case the 95% Cl for UroVysion is greater than the BTAstat score minus 15%.

Image /page/14/Figure/2 description: This image is labeled as "Figure 1" and the title is "Comparison of Three Detection Methods Relative to Cystoscopy/Histology". The image appears to be the title of a figure, possibly from a research paper or presentation. The text is centered and in a clear, readable font.

Image /page/14/Figure/3 description: This bar graph compares the agreement percentages of UroVysion, BTAstat, and Cytology. The graph displays the agreement percentages for 'Agreement (+)', 'Agreement (-)', and 'Overall Agreement'. For 'Agreement (+)', UroVysion has approximately 70%, BTAstat has approximately 50%, and Cytology has approximately 25%. For 'Agreement (-)', UroVysion has approximately 65%, BTAstat has approximately 70%, and Cytology has approximately 90%. For 'Overall Agreement', UroVysion has approximately 65%, BTAstat has approximately 60%, and Cytology has approximately 65%.

A summary of the percent agreement of the three detection methods in the group of patients treated with BCG within the last 3 months is shown in Figure 2 (unique patient visits). In this group, the UroVysion test's two tail lower 95% Cl for percent agreement of positive, negative and overall results was 64.0%. 40.6% and 55.1%, respectively. On the corresponding dataset assayed with the BTAstat test, the scores minus 15% were 54.2%, 27.3% and 36.3%, respectively. Thus, the criteria for substantial equivalence of the UroVysion assay to the BTAstat test were met; the 95% Cls for UroVysion are greater than the BTAstat scores minus 15%. This is represented graphically in Figure 2; the error bars represent the upper and lower 95% Cls for the UroVysion test results and the test score minus 15% for the BTAstat test results. Again, as shown in the figure, in each case the 95% Cl for UroVysion is greater than the BTAstat score minus 15%.

{15}------------------------------------------------

Image /page/15/Figure/1 description: This image is titled "Figure 2" and describes a comparison of three detection methods relative to cystoscopy/histology on patients treated with BCG within 3 months of a study visit. The title is centered and written in a clear, bold font. The text provides context for the figure, indicating that it will present a comparison of different detection methods in a specific patient population.

Image /page/15/Figure/2 description: This bar graph compares the agreement between UroVysion, BTAstat, and Cytology. The x-axis shows the agreement categories: Agreement (+), Agreement (-), and Overall Agreement. The y-axis represents the percentage, ranging from 0 to 120. For Agreement (+), UroVysion is around 92%, BTAstat is around 68%, and Cytology is around 30%.

The UroVysion test and the BTAstat test were each compared to cytology on patients positive for recurrence, as determined by cystoscopy/histology; the results are shown in Tables 14 and 15. Cytology did not pick up any cases that were negative by FISH (Table 14). Cytology was positive in 2 cases found negative by BTAstat (Table 15).

# Table 14

#### Comparison of FISH vs. Cytology Results in Patients Positive for Recurrence Cytology

| FISH | | | Total |
|-------|----|----|-------|
| | + | - | |
| + | 16 | 27 | 43 |
| - | 0 | 18 | 18 |
| Total | 16 | 45 | 61 |

was scored inconclusive for cytology and not included in this table.

# Table 15 Comparison of BTAstat vs. Cytology Results in Patients Positive for Recurrence

| | Cytology | | |
|---------|----------|----|-------|
| BTAstat | + | - | Total |
| + | 15 | 16 | 31 |
| - | 1 | 29 | 30 |
| Total | 16 | 45 | 61 |

case was scored inconclusive for cytology and not included in this table.

Company Confidential, Vysis, Inc.

{16}------------------------------------------------

The results for the percent agreement of results for the UroVysion test (FISH), the BTAstat test and cytology are summarized in Table 16 (per patient office visit).

| Table 16 | | | | |
|-----------------------------|--------------------------|-------|---------|----------|
| Summary: Methods Comparison | | | | |
| | | FISH | BTAstat | Cytology |
| Overall | Agreement of (+) Results | 71.0% | 50.0% | 26.2% |
| | Agreement of (-) Results | 65.8% | 69.3% | 89.1% |
| | Overall Agreement | 67.6% | 62.5% | 66.7% |
| BCG<br>Treatment | Agreement of (+) Results | 92.3% | 69.2% | 30.8% |
| | Agreement of (-) Results | 61.5% | 42.3% | 84.6% |
| | Overall Agreement | 71.8% | 51.3% | 66.7% |

Table 17 shows a head to-head comparison of the results from the UroVysion test and the BTAstat test on those cases (unique office visits) with informative results for both tests. The concordance between the two tests was 61.9%.

#### Table 17 Concordance of FISH vs. BTAstat BTAstat

| FISH | + | - | Total |
|-------|----|-----|-------|
| + | 41 | 42 | 83 |
| - | 25 | 68 | 93 |
| Total | 66 | 110 | 176 |

An analysis of the discordant results is presented in Table 18. Of the cases positive by FISH and negative by BTAstat, 21 (50.0%) were positive by either cytology or cystoscopy/histology, or both, including 4 Tis tumors and 1 T2 tumor (Table 18). Of the 25 cases negative by FISH and positive by BTAstat, only 3 (12.0%) were positive by one or both of the comparative methods.

| | Table 18 | | |
|---------------------------------------|------------------------|------------------------|--|
| FISH vs. BTAstat: Discordant Analysis | | | |
| | FISH "+" / BTAstat "-" | FISH "-" / BTAstat "+" | |
| N | 42 | 25 | |
| Cytology "+" | 7 (16.7%) | 1 (4.0%) | |
| Cysto/Histo "+" | 15 (35.7%) | 2 (8.0%) | |
| Ta | 6 | 1 | |
| T1 | -- | -- | |
| T2 | 1 | -- | |
| Tis | 4 | -- | |
| Unk | 1 | 1 | |
| Pos/No Biopsy | 3 | -- | |
| Cytology "+" or<br>Cysto/Histo "+" | 21 (50.0%) | 3 (12.0%) | |

Note: One (1) case showed both positive cytology and positive cystoscopy/histology in the FISH "+"/BTAstat "-" group.

{17}------------------------------------------------

#### Longitudinal Study

As a continuation of the multi-center prospective study described above, office visit information (without FISH or BTAstat testing) was subsequently collected for patients who had not experienced a relapse (i.e., cystoscopy/histology negative) for a period of approximately 1 year from their last visit during the main phase of the trial. Of the 114 eligible patients, office visit information was collected from 105. A total of 335 patient visits were reported, resulting in 299 usable office visits, representing 104 unique patients (Note: for 1 patient the only office visit reported was an ineligible visit). The 36 unusable visits included 21 that did not meet eligibility criteria and 15 with suspicious cystoscopies but no histology. For patients who experienced a recurrence (as determined by cystoscopy/histology), the first positive visit was used. For non-recurring patients, the last negative visit was used for those patients with more than one visit.

The results showed recurrence in a greater percentage of patients in the FISH positive, cystoscopy/histology negative group than in the FISH negative, cystoscopy/histology negative group; the difference was statistically significant (p=0.014, x2, 1 df). The results are summarized in Table 19.

| | Table 19<br>Longitudinal Study Summary | | |
|------------------------------|----------------------------------------|---------------------|--|
| | FISH -/cysto:histo - | FISH+/cysto:histo - | |
| % Recurrence | 19.12% (13/68) | 41.67% (15/36) | |
| Difference in rates (95% CI) | 22.55 % (3.93%–41.17%) | | |
| | | p = 0.014* | |
| Follow-up time (months): | | | |
| No recurrence | 14.3±3.9 | 13.5±3.4 | |
| Recurrence | 11.0±5.8 | 6.9±4.4 | |
| Recurrence Details^: | | | |
| Stage | | | |
| Ta G1 | 5 | 3 | |
| Ta G2,3 | 0 | 1 | |
| T1 | 2 | 0 | |
| Tis | 0 | 1 | |
| Grade | | | |
| 1 | 5 | 5 | |
| 2 | 1 | 1 | |
| 3 | 1 | 1 | |

1 df

Biopsy was not performed in 8 cases (4 FISH+/cysto:histo-, 4 FISH-/cysto:histo-). Slides were not provided by collection site for assessment by the central pathologist in 6 cases (4 FISH+/cysto:histo-2 FISH-/cysto:histo-). No stage was assigned in 2 FISH+/cysto:histo- cases.

{18}------------------------------------------------

Probability estimates for non-recurrence at various intervals were determined using the product-limit method for right-censored data (i.e. Kaplan-Meier). Analysis of homogeneity between the two patient groups (anticipatory positives, and true negatives) was determined using the log-rank and Wilcoxon chi-square statistic. As shown in Figure 3, both methods show that a statistical difference was maintained throughout the follow-up period between the FISH + /cysto:histo - and the FISH -/cysto:histo - groups.

Image /page/18/Figure/2 description: This image is labeled Figure 3 and shows the recurrence-free survival for patients in the FISH -/cysto:histo - vs. FISH +/cysto:histo - Groups. The figure is likely a survival curve comparing the two groups. The title indicates that the study is focused on the recurrence-free survival of patients.

Image /page/18/Figure/3 description: This image is a Kaplan-Meier survival curve comparing two groups: FISH+/cysto:histo- and FISH-/cysto:histo-. The x-axis represents time in months, ranging from 0 to 25, while the y-axis represents the survival probability, ranging from 0.0 to 1.0. The FISH+/cysto:histo- group has a lower survival rate than the FISH-/cysto:histo- group. A table below the graph shows the results of statistical tests between the two groups, with Log-Rank Chi-Square of 8.7454 (p=0.0031) and Wilcoxon Chi-Square of 10.6166 (p=0.0011).

{19}------------------------------------------------

#### HYBrite/VP 2000 Validation

The VP2000 is considered to be a class I, exempt device according to 21 CFR § 864.3800 Automated slide stainer, and 21 CFR § 864.3875 Automated tissue processor. The function of the VP2000 is consistent with both of the above paragraphs from the CFR. Indeed, except for minor modifications the device is exactly the same device as the custom OEM device bought and sold by Zeiss during the past decade as a class I device for cytology laboratories.

The paragraphs from the CFR are reproduced below:

21 CFR § 864.3800 Automated slide stainer. (a) Identification. An automated slide stainer is a device used to stain histology, cytology and hematology slides for diagnosis. (b) Classification. Class I. The device is exempt from the premarket notification . procedures in Subpart E of Part 807 of this chapter.

21 CFR & 864.3875 Automated tissue processor. (a) Identification. An automated tissue processor is an automated system used to process tissue specimens for examination through fixation, dehydration, and infiltration. (b) Classification. Class 1. The device is exempt from the premarket notification procedures in Subpart E of Part 807 of this chapter.

A validation study was conducted to determine if the recommended specimen pretreatment protocol and assay for the UroVysion Kit performed the same® whether done manually by technician or by semi-automated using the VP2000 Sample Processor and HYBrite instruments.

Study specimens consisted of three human urine pools prepared from voided urine specimens obtained from normal donors. Study specimens used in the Assay Interference Study, Protocol 99-402R (see Appendix B for protocol and study report) were also used as part of this study. Each of the 29 substances which were spiked into aliquots of each of the three pools at two different concentrations were tested on three separate VP-2000 and HYBrite instruments and compared to results obtained in the manual study.

Quality evaluations from samples of the 23 different compounds and 6 preservatives tested produced equivalent results using the UroVysion Kit and FISH Pretreatment Kit for all concentrations tested and across all three instrument set-ups.

Normal urine pools (unspiked) and manual assay results from the Interference Study Protocol, 99-402R were used as controls. All compounds and preservatives identified in Table 20 performed within 2 standard deviations or 20% of the control pools, supporting the conclusion that the manual and semiautomated methods are equivalent.

{20}------------------------------------------------

| Substance | Concentrations | Results- Manual vs<br>Semi-Automation |
|--------------------------------------|------------------------------------------------------------------------|---------------------------------------|
| Possible Urine Constituents | | |
| Albumin | 0.5 g/dL and 1.0 g/dL | Equivalent. |
| Ascorbic Acid | 2.5 g/dL and 5 g/dL | Equivalent. |
| Bilirubin (unconjugated) | 1 mg/mL and 2 mg/mL | Equivalent. |
| Hemoglobin | 50 mg/mL and 100 mg/mL | Equivalent. |
| IgG | 5 mg/dL and 10 mg/dL | Equivalent. |
| Red Blood Cells (human) | 5 x 105 cells/mL and 1 x 106 cells/mL | Equivalent. |
| White Blood Cells (human) | 5 x 105 cells/mL and 1 x 106 cells/mL | Equivalent. |
| Sodium Chloride | 365 mg/dL and 730 mg/dL | Equivalent. |
| Uric Acid | 125 mg/dL and 250 mg/dL | Equivalent. |
| Caffeine | 58.5 mg/dL and 117 mg/dL | Equivalent. |
| Ethanol | 0.5% (v/v) and 1% (v/v) | Equivalent. |
| Nicotine | 14 mg/dL and 28 mg/dL | Equivalent. |
| Possible Microbial Contaminants | | |
| Candida albicans | 1.25 x 1010 CFU/mL and 2.5 x 1010 CFU/mL | Equivalent. |
| Escherichia coli | 1.25 x 1010 CFU/mL and 2.5 x 1010 CFU/mL | Equivalent. |
| Pseudomonas aerugenosa | 1.25 x 1010 CFU/mL and 2.5 x 1012 CFU/mL | Equivalent. |
| Therapeutic Agents | | |
| Acetaminophen | 2.6 g/dL and 5.2 g/dL | Equivalent. |
| Acetylsalicylic Acid | 2.6 g/dL and 5.2 g/dL | Equivalent. |
| Ampicillin | 300 mg/dL and 600 mg/dL | Equivalent. |
| BCG | 10 mg/dL and 20 mg/dL | Equivalent. |
| Doxorubicin-HCl | 5 mg/dL and 10 mg/dL | Equivalent. |
| Mitomycin C | 5 mg/dL and 10 mg/dL | Equivalent. |
| Nitrofurantoin | 25 mg/dL and 50 mg/dL | Equivalent. |
| Phenazopyridine-HCl | 100 mg/dL and 200 mg/dL | Equivalent. |
| Thiotepa | 5 mg/dL and 10 mg/dL | Equivalent. |
| Trimethoprin | 25 mg/dL and 50 mg/dL | Equivalent. |
| Preservatives | | |
| Vysis, Inc. standard:<br>2% Carbowax | 2% Carbowax/50% ethanol solution (33 ml urine with 17 mL preservative) | Equivalent. |
| UroCor, Inc. fixative | 50/50 with urine | Equivalent. |
| CytRichRed (Autocyte) | 50/50 with urine | Equivalent. |
| Saccamono's solution | 50/50 with urine | Equivalent. |
| PreservCyt solution (Cytyc) | 50/50 with urine | Equivalent. |
| 100% Ethanol | 50/50 with urine | Equivalent. |

### Table 20 Manual versus Semi-Automation Study Results

#### Conclusions

The clinical studies described in this document demonstrate that the performance of UroVysion Kit is safe and effective. The performance of the UroVysion Kit is also supported by the Vysis Quality Control procedures. When the UroVysion Kit is used as instructed in the package insert, the above statements describe its performance.

{21}------------------------------------------------

Image /page/21/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its wings or body. The bird is positioned above the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA", which is arranged in a circular fashion around the bird. The logo is in black and white.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Russel K. Enns, Ph.D. Vice President of Regulatory Affairs Vysis, Inc. 3100 Woodcreek Drive Downers Grove, IL 60515

Re: K013785

> Trade Name: UroVysion™ Bladder Cancer Recurrence Kit Regulation Number: 21 CFR § 866.6010 Regulation Name: Tumor-associated antigen immunological test system Regulatory Class: Class II Product Code: MMW Dated: November 13, 2001 Received: November 14, 2001

FEB 0 8 2002

Dear Dr. Enns:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{22}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and t additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/odrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{23}------------------------------------------------

# 510(k) Number (IF KNOWN): | DJ3285

DEVICE NAME: Vysis™, Inc. UroVysion™ Bladder Cancer Recurrence Kit

#### INDICATIONS FOR USE:

The UroVysion Bladder Cancer Recurrence Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder. Results from the UroVysion Kit are intended for use as a noninvasive method for monitoring for turnor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

Note: No change from the current, cleared, indications for use (K011031)

Sousan. S. Altare

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number. K013785

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter-Use (Optimal Format 1-2-96)